DelveInsight launched a new report on Primary Hyperoxaluria Epidemiology Forecast, 2030.
Primary hyperoxaluria (PH) is a family of ultra-rare, life-threatening genetic disorders that cause complications in the kidneys. There are three known genetic types of PH, each resulting from a mutation in one of three different genes. These genetic mutations cause enzyme deficiencies that manifest in the overproduction of a substrate called oxalate. Abnormal production and accumulation of oxalate lead to recurrent kidney stones, nephrocalcinosis, and chronic kidney disease that may progress to an end-stage renal disease requiring regular dialysis and a dual liver-kidney transplant.
DelveInsight’s ‘Primary Hyperoxaluria Epidemiology Forecast to 2030‘ report delivers an in-depth understanding of the disease, historical and forecasted Primary Hyperoxaluria epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Some of the key highlights from the Primary Hyperoxaluria Epidemiology Report:
As per the Orphanet, Primary Hyperoxalurias (PH) prevalence ranges from 1-3/1 000 000 and the estimated incidence is between 1-2/10 000 000 per year with no differences between sexes. There are higher rates reported in isolated populations, especially in the Middle East and North Africa. A significant proportion of patients are diagnosed in adulthood which implies an important underdetection of patients. PH1 accounts for 85% of patients, PH2 8-10%, and PH3 5-7%.
PH1 is estimated to account for 1%-2% of children with end-stage renal disease (ESRD) [Harambat et al 2012].
Clinical estimates of the prevalence of PH1, primarily from European studies, range from one to three in 1,000,000 [van Woerden et al 2003, Cochat & Rumsby 2013].
PH1 is estimated to occur in 1:120,000 live births in Europe [Cochat & Rumsby 2013]. Since phenotypic heterogeneity ranges from severe disease in infancy to adults with recurrent stones, and since the advanced disease is present in 20%-50% at the time of diagnosis, under-diagnosis likely occurs.
Visit for more @ Primary Hyperoxaluria Epidemiology Insights
Scope of the Primary Hyperoxaluria Epidemiology report:
The Primary Hyperoxaluria report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis, and treatment patterns.
The Primary Hyperoxaluria Epidemiology Report and Model provide an overview of the risk factors and global trends of Primary Hyperoxaluria in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
The report provides insight into the historical and forecasted patient pool of Primary Hyperoxaluria in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan.
The report helps to recognize the growth opportunities in the 7MM concerning the patient population.
The report assesses the disease risk and burden and highlights the unmet needs of Primary Hyperoxaluria.
The report provides the segmentation of the Primary Hyperoxaluria epidemiology.
Table of Contents:
1. Key Insights
2. Executive Summary of Primary Hyperoxaluria
3. Primary Hyperoxaluria Epidemiology Overview at a Glance
4. Primary Hyperoxaluria: Disease Background and Overview
5. Epidemiology and Patient Population
6. Case Reports
7. Country Wise-Epidemiology of Primary Hyperoxaluria
9. DelveInsight Capabilities
11. About DelveInsight
DelveInsight’s ‘Primary Hyperoxaluria-Market Insights, Epidemiology, and Market Forecast—2030’ report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),
“Primary Hyperoxaluria Pipeline Insight, 2021” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Primary Hyperoxaluria market. A detailed picture of the Primary Hyperoxaluria pipeline landscape is provided, which includes the disease overview and Primary Hyperoxaluria treatment guidelines.
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States